treatment of urban cutaneous leishmaniasis in iran with cycloguanil pamoate
نویسندگان
چکیده
one hundred one cases of urban cutaneous leishmaniasis from mashad and teh ran were placed under treatment with either one or two sim ultaneous standa rd doses of cycloguanil parnoate. out of 101 patients, 96 were followed until the 120th day; 31 (31 per cent ) recovered with in 60 days, ?3 ('3 per cent) recovered utter between 60 and i70 days, and 42 (42 per cent) did not respond. a higher recovery rate was o bserved in subjects who received two simultaneous doses of the drug (38 per cent cithin 60 days), recovery ra te was also higher in the patients from tehran who were children aged 7 to 12 yea rs, however, our results indicate that carnolar is less effective than pentavalent an imonial (glucantime). the side-effects of the drug were tenderness (83 per cent), induration (27 per cent) fever (6 per cent) and abscess (2 per cent). no changes in complete blood count were observed. the incidence of adverse drug reactions was higher when two simultaneous doses were given.
منابع مشابه
Antimonial treatment failure rate in patients with cutaneous leishmaniasis
Background: Despite advances in diagnosis and treatment, leishmaniasis is now considered a severe public health problem, particularly in developing countries, such as Iran. Leishmaniasis is among the six most important, parasitic diseases of the world affecting 88 countries in almost every continent. The disease is complex with different clinical presentations such as visceral, cutaneous and mu...
متن کاملUrban American cutaneous leishmaniasis*
1. Delyon J, Ortonne N, Benayoun E, Moroch J, Wolkenstein P, Sbidian E, et al. Lowdose methotrexate-induced skin toxicity: Keratinocyte dystrophy as an histologic marker. J Am Acad Dermatol. 2015;73:484-90. 2. Yélamos O, Català A, Vilarrasa E, Roé E, Puig L. Acute severe methotrexate toxicity in patients with psoriasis: a case series and discussion. Dermatology. 2014;229:306-9. 3. Troeltzsch M,...
متن کاملCycloguanil pamoate in the treatment and suppression of malaria in the Gambia, West Africa.
Cycloguanil pamoate is an antimalarial drug recently developed by Thompson et al. (1963) in the United States. It is closely allied to the existing drugs, proguanil and pyrimethamine, and when administered intramuscularly is slowly released and thus maintains an effective antiplasmodial blood level for a prolonged period. The advantages offered by a repository drug become obvious when considera...
متن کاملOral Zinc Sulfate in the treatment of acute cutaneous Leishmaniasis
Background: Different local and systemic modalities are suggested in the treatment of cutaneous leishmaniasis (CL), but the pentavalent antimony compounds are still considered as the first line of treatment. Regarding to increase in clinical drug resistance, adverse effects and low compliance of patient, efforts for finding a more effective and safer drug continue. Objectives: To evaluate...
متن کاملSporotrichoid Cutaneous Leishmaniasis in Central Iran
More than 90% of patients infected with cutaneous leishmaniasis live in Afghanistan, the Middle East, Algeria, Brazil, and Peru. Cutaneous leishmaniasis in Iran is caused by Leishmania tropica and Leishmania major. Most skin lesions evolve from papular to nodular, to ulcerative form with a central depression surrounded by a raised indurate border. Some lesions persist as nodules or plaques. Mul...
متن کاملCutaneous leishmaniasis treatment.
The causative species of cutaneous leishmaniasis determines the clinical features and courses, and treatments. Intralesional or systemic antimonials are the gold standard for the treatment of these diseases. However, as for visceral leishmaniasis, other therapeutic options appear promising. Paromomycin ointments are effective in Leishmania major, L. tropica, L. mexicana, and L. panamensis lesio...
متن کاملمنابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
acta medica iranicaجلد ۱۹۷۲، شماره ۱۲، صفحات ۱۲۵-۱۳۰
میزبانی شده توسط پلتفرم ابری doprax.com
copyright © 2015-2023